Patents Assigned to COGNITIVE RESEARCH ENTERPRISES, INC
-
Patent number: 11173140Abstract: Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, com-prising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecut-ive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a dis-ease or condition associated with neuronal or synaptic loss according to the disclosed regimens.Type: GrantFiled: July 16, 2019Date of Patent: November 16, 2021Assignee: COGNITIVE RESEARCH ENTERPRISES, INC.Inventor: Daniel L. Alkon
-
Publication number: 20210023048Abstract: Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecutive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.Type: ApplicationFiled: October 1, 2020Publication date: January 28, 2021Applicant: COGNITIVE RESEARCH ENTERPRISES, INC.Inventor: Daniel L. ALKON
-
Patent number: 10821079Abstract: The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.Type: GrantFiled: November 13, 2012Date of Patent: November 3, 2020Assignee: Cognitive Research Enterprises, Inc.Inventors: Daniel L. Alkon, Thomas J. Nelson
-
Publication number: 20200331875Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: ApplicationFiled: June 17, 2020Publication date: October 22, 2020Applicant: COGNITIVE RESEARCH ENTERPRISES, INC.Inventors: Thomas J. NELSON, Daniel L. ALKON
-
Patent number: 10696644Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: GrantFiled: May 1, 2019Date of Patent: June 30, 2020Assignee: COGNITIVE RESEARCH ENTERPRISES, INC.Inventors: Thomas J. Nelson, Daniel L. Alkon
-
Publication number: 20190365706Abstract: Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, com-prising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecut-ive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a dis-ease or condition associated with neuronal or synaptic loss according to the disclosed regimens.Type: ApplicationFiled: July 16, 2019Publication date: December 5, 2019Applicant: COGNITIVE RESEARCH ENTERPRISES, INC.Inventor: Daniel L. ALKON
-
Publication number: 20190270715Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturted fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono and polyunsaturated fatty acids.Type: ApplicationFiled: May 1, 2019Publication date: September 5, 2019Applicant: COGNITIVE RESEARCH ENTERPRISES, INC.Inventors: Thomas J. NELSON, Daniel L. ALKON
-
Patent number: 10323011Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: GrantFiled: July 20, 2015Date of Patent: June 18, 2019Assignee: COGNITIVE RESEARCH ENTERPRISES, INC.Inventors: Thomas J. Nelson, Daniel L. Alkon
-
Patent number: 10137106Abstract: The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.Type: GrantFiled: October 31, 2017Date of Patent: November 27, 2018Assignee: Cognitive Research Enterprises, Inc.Inventor: Daniel L. Alkon
-
Publication number: 20180311209Abstract: Dosing regimens and methods are disclosed for upregulating on protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of administration or dosing for three consecutive weeks. Also described are methods for improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens.Type: ApplicationFiled: October 8, 2016Publication date: November 1, 2018Applicant: Cognitive Research Enterprises, Inc.Inventor: Daniel L. ALKON
-
Patent number: 9974832Abstract: The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.Type: GrantFiled: February 11, 2008Date of Patent: May 22, 2018Assignee: Cognitive Research Enterprises, Inc.Inventors: Ofer Zohar, Daniel L. Alkon
-
Patent number: 9597312Abstract: The present disclosure provides methods of treating a cognitive disorder associated with abnormal dendritic spines, such as Fragile X Syndrome, Fragile X Associated Tremor/Ataxia Syndrome, autism, or mental retardation, using PKC activators.Type: GrantFiled: August 19, 2011Date of Patent: March 21, 2017Assignee: Cognitive Research Enterprises, Inc.Inventors: Miao-kun Sun, Daniel L. Alkon
-
Patent number: 9539235Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: GrantFiled: March 27, 2013Date of Patent: January 10, 2017Assignee: COGNITIVE RESEARCH ENTERPRISES, INCInventors: Rene Etcheberrigaray, Daniel L. Alkon